- Home
- NMRK vs GH Comparison
NMRK vs GH Comparison
Compare NMRK & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMRK
- GH
- Stock Information
- Founded
- NMRK 1929
- GH 2011
- Country
- NMRK United States
- GH United States
- Employees
- NMRK N/A
- GH N/A
- Industry
- NMRK Real Estate
- GH Medical Specialities
- Sector
- NMRK Finance
- GH Health Care
- Exchange
- NMRK Nasdaq
- GH Nasdaq
- Market Cap
- NMRK 2.5B
- GH 2.7B
- IPO Year
- NMRK 2017
- GH 2018
- Fundamental
- Price
- NMRK $14.96
- GH $30.98
- Analyst Decision
- NMRK Buy
- GH Strong Buy
- Analyst Count
- NMRK 3
- GH 15
- Target Price
- NMRK $16.17
- GH $39.93
- AVG Volume (30 Days)
- NMRK 1.2M
- GH 2.2M
- Earning Date
- NMRK 11-05-2024
- GH 11-06-2024
- Dividend Yield
- NMRK 0.81%
- GH N/A
- EPS Growth
- NMRK 320.81
- GH N/A
- EPS
- NMRK 0.30
- GH N/A
- Revenue
- NMRK $2,613,228,000.00
- GH $692,256,000.00
- Revenue This Year
- NMRK $8.85
- GH $31.00
- Revenue Next Year
- NMRK $12.16
- GH $17.55
- P/E Ratio
- NMRK $49.08
- GH N/A
- Revenue Growth
- NMRK 12.15
- GH 29.20
- 52 Week Low
- NMRK $7.72
- GH $15.81
- 52 Week High
- NMRK $16.10
- GH $37.04
- Technical
- Relative Strength Index (RSI)
- NMRK 48.33
- GH 70.13
- Support Level
- NMRK $14.48
- GH $28.45
- Resistance Level
- NMRK $15.44
- GH $32.26
- Average True Range (ATR)
- NMRK 0.57
- GH 1.70
- MACD
- NMRK -0.05
- GH 0.39
- Stochastic Oscillator
- NMRK 64.71
- GH 75.19
About NMRK Newmark Group Inc.
Newmark Group Inc is a commercial real estate advisory firm. It offers services, including leasing and corporate advisory services, investment sales, commercial mortgage brokerage, appraisal and valuation, project management, and property, among others. Newmark offers a diverse array of integrated services and products designed to meet the full needs of both real estate investors/owners and occupiers. The company provides real estate strategic consulting and systems integration services to CFI's clients including many Fortune and Forbes companies, owner-occupiers, government agencies, healthcare, and higher education clients.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched a lab-developed test version of Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.